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Abstract Dynamic
13N-ammonia PET is used to assess
ammonia metabolism in brain, liver and muscle based on
kinetic modeling of metabolic pathways, using arterial blood
13N-ammonia as input function. Rosenspire et al. (1990)
introduced a solid phase extraction procedure for fraction-
ation of
13N-content in blood into
13N-ammonia,
13N-urea,
13N-glutamine and
13N-glutamate. Due to a radioactive half-
life for
13N of 10 min, the procedure is not suitable for blood
samples taken beyond 5–7 min after tracer injection. By
modifying Rosenspire’s method, we established a method
enabling analysis of up to 10 blood samples in the course of
30 min. The modified procedure was validated by HPLC and
by 30-min reproducibility studies in humans examined by
duplicate
13N-ammonia injections with a 60-min interval.
Blood data from a
13N-ammonia brain PET study (from
Keiding et al. 2006) showed: (1) time courses of
13N-
ammonia fractions could be described adequately by double
exponential functions; (2) metabolic conversion of
13N-
ammonia to
13N-metabolites were in the order: healthy
subjects > cirrhotic patients without HE > cirrhotic patients
with HE; (3) kinetics of initial tracer distribution in tissue can
be assessed by using total
13N-concentration in blood as
input function, whereas assessment of metabolic processes
requires
13N-ammonia measurements.
Keywords
13N-ammonia metabolism.Positronemission
tomography.Ammoniametabolites.Solid-phase
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Introduction
Hepatic encephalopathy (HE) is a severe neurological
condition arising secondary to liver failure. Hyperammone-
mia is considered a major causative factor because most
patients with HE have elevated blood concentrations of
ammonia, which in high concentrations is neurotoxic
(Cooper and Plum 1987; Jones and Basile 1998; Cooper
2001; Butterworth 2002: Johansen et al. 2007; Iversen et al.
2009). Dynamic
13N-ammonia PET has been used in
humans to assess ammonia metabolism in brain (Lockwood
et al. 1979, 1984, 1991; Ahl et al. 2004; Weissenborn et al.
2004; Keiding et al. 2006; Sørensen and Keiding 2007a;
Sørensen et al. 2009; Berding et al. 2009), liver (Keiding et
al. 2001, 2005; Sørensen and Keiding 2007b) and muscle
(Nishiguchi et al. 2003). The PET procedure encompasses
intravenous injection of
13N-ammonia tracer followed by
dynamic measurements of radioactivity concentrations in
arterial blood (samples) and tissue (PET camera). Data are
analyzed by fitting kinetic models of the metabolic pathways
to the time courses of the tissue radioactivity concentrations,
using the time course of radioactivity concentrations in blood
as input function. However, appearance of
13N-urea,
13N-
glutamine and other
13N-labelled amino acids in blood
(Cooper et al. 1979; Lockwood et al. 1979;N i e v e se ta l .
1986; Rosenspire et al. 1990; Keiding et al. 2006)
complicates the kinetic analysis. Consequently the analysis
of dynamic
13N-ammonia PET studies is sometimes limited
to assessment of distribution and transport processes across
the plasma membrane during the very first minutes after
In this paper, the term ammonia refers to the sum of unionized NH3
and ionized NH4
+
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13N-radioactivity concentration in
blood as input function (Ahl et al. 2004). In agreement with
this, we showed that formation of
13N-metabolites can be
ignored for the assessment of the initial distribution of tracer
(Sørensen and Keiding 2006). However, calculation of
parameters of steady-state metabolic processes requires the
use of metabolite-corrected input functions, i.e.
13N-ammonia
concentrations (Keiding et al. 2006, Sørensen and Keiding
2006;B a s se ta l .2009).
Various attempts have been made to fractionate un-
metabolized
13N-ammonia and
13N-labelled metabolites in
blood (Cooper et al. 1979; Lockwood et al. 1979; Nieves et
al. 1986; Rosenspire et al. 1990). The most robust method
was published by Rosenspire et al. (1990) who introduced a
sequential solid phase extraction procedure which combines
the use of cation and anion exchange resins, allowing for
fractionation of the
13N-content in blood into
13N-acidic
amino acids,
13N-ammonia,
13N-neutral amino acids, and
13N-urea. However, only results from blood samples taken
up to 5 min after injection of
13N-ammonia in healthy
human subjects were published (Rosenspire et al. 1990).
Due to the radioactive half-life of
13N-nitrogen of 10 min
the method is not suitable for blood samples taken beyond
5–7 min after injection of the
13N-ammonia tracer. By
modifying Rosenspire’s method, we established a method
which enables us to analyze up to 10 blood samples in the
course of a 30-min dynamic human
13N-ammonia PET
study (Keiding et al. 2006). In the present study we describe
our technical modifications of Rosenspire’s method and give
detailed reports of the
13N-metabolite measurements in
Keiding et al. (2006), including validation by means of
radio-HPLC measurements and studies of reproducibility in
30-min studies of human subjects who were given two
successive
13N-ammonia injections.
Material and methods
Human subjects
The method was used to determine
13N-metabolites in
blood samples in a brain PET study of 5 healthy subjects,
8 cirrhotic patients with type C HE, and 7 cirrhotic patients
with neither overt, nor minimal HE (Keiding et al. (2006)
and here we give a detailed report of the technical
procedure and the
13N-metabolite measurements. Data from
another five patients with compensated liver cirrhosis who
were given two injections of
13N-ammonia at a 60-min
interval are also included.
13N-ammonia was produced at the radiochemistry
facility of the PET Centre, Aarhus University Hospital,
with a radiochemical purity >98% and a specific radioac-
tivity of 30–40 GBq/µmol. 500 MBq
13N-ammonia was
injected intravenously over 15 s, and arterial blood samples
were collected via a small catheter placed in a radial artery
(Artflon Becton Dickinson, Swindon, UK) in heparinized
1.5 ml Eppendorf tubes after 1, 2, 3, 5, 7, 10, 15, 20, 25,
and 30 min.
All studies were approved by the Ethics Committee of
Aarhus County, and informed consent was obtained from
each subject. No complications to the procedure were
observed.
Preparation of solid phase extraction columns
Three columns for the sequential solid phase extraction
procedure were prepared at the PET Centre. Plungers from
1 ml Tuberculin syringes (Codan Medical Aps, Rødby,
Denmark) were removed, and quartz wool was put into the
syringes to fix exchange resins in the syringes. The resins
were conditioned immediately before each study. All
chemicals for conditioning the ion exchange resins were
purchased from Sigma-Aldrich Denmark, Vallensbæk Strand,
Denmark. Column 1: Dowex 1X8–50 anion exchange resin,
20–50 mesh, chloride form was converted to the acetate form
by flushing the resin with at least 10 volumes of 0.75 M
sodium acetate trihydrate solution. 0.5–0.6 ml of this anion
exchange resin in acetate form was manually filled in the
1 ml syringe. Column 2: AG 50 W-X8 resin hydrogen form
100–200 mesh (Bio-Rad Laboratories, Hercules, CA) was
converted to tris(hydroxymethyl)aminomethane (TRIS) form
by flushing the resin with at least 10 volumes of a solution
prepared from 0.8 M solution of TRIS acetate (freshly
prepared from equal molar amounts of TRIS and glacial
acetic acid). 250–350 µL of this resin were manually filled in
the 1 ml syringe. Column 3: AG 50 W-X8 resin hydrogen
form 100–200 mesh (Bio-Rad Laboratories, Hercules, CA)
was flushed with at least 10 volumes of Millipore water. 250–
350 µL of this resin were manually filled in 1 ml syringes.
The employed Bio-Rad AG 50 W-X8 resin is chemically
equivalent to the originally used Dowex 50(H
+) resin by
Rosenspire et al. (1990).
The original method by Rosenspire et al. (1990)
comprised elution of resin-bound radioactivity with 2 M
potassium chloride solution for radioactivity measurements
in a well counter. In our adaptation, the syringes, containing
the resins and trapped
13N-metabolites, were placed directly
in the well counter.
Solid phase extraction procedure
A volume of 0.5 ml whole-blood was added to 0.5 ml of a
10 wt% solution of sulfosalicylic acid. After vigorous
shaking, the samples were centrifuged for 2 min at
13,000 rpm to precipitate proteins. For solid phase
extraction procedures, Alltech Visiprep® manifolds were
50 Metab Brain Dis (2010) 25:49–56employed. As illustrated in Fig. 1, the supernatant from the
worked-up blood sample was transferred on to Column 1
containing the acetate-conditioned resin, followed by 5–
10 s suction through the resin. The resin was washed with
4 ml of Millipore water. The column with resin-bound
radioactivity was transferred into a counting tube and
radioactivity was measured in a well counter (
13N-contain-
ing acidic amino acids; mainly
13N-glutamate). The mixed
eluate and Milipore water was then sucked through Column
2, containing TRIS-conditioned resin. The resin was
washed with 2×3.5 ml Millipore water, and resin-bound
radioactivity (
13N-ammonia) was measured in a well
counter. The mixed eluate and Milipore water was sucked
through Column 3, containing resin in hydrogen form. This
resin was washed with 3×3.5 ml water and the resin-
bound radioactivity counted in a well counter (
13N-labeled
neutral amino acids; mainly
13N-glutamine). According to
Rosenspire et al. (1990), the radioactivity in the final
washing solution is attributed to
13N-urea. The solution
(final eluate+Milipore water) was collected in a pre-
weighed plastic beaker and 5 ml of the solution was
counted in a well counter. The pre-weighed plastic beaker
was weighed again, and the amount of radioactivity in the
5 ml solution was related to the entire final volume.
To ensure a high through-put of samples, we used 2
Visiprep manifolds simultaneously.
Counting statistics
Count rates were generally lower for blood samples taken at
late time points than for blood samples taken earlier
because of the radioactive half-life of 10 min resulting in
less accurate counting statistics (Table 1). The measurement
accuracy was slightly better for the first two fractions, i.e.
for
13N-glutamate and
13N-ammonia than for the
13N-
glutamine and
13N-urea fractions, probably due to adsorp-
tion of
13N-substances to the plastic tubes during elution
and transfer of the liquids (Fig. 1 and Table 1). Further-
more, the relative large measurement uncertainty for
13N-
urea may be explained by the poor counting statistics due to
dilution of 0.5 ml blood to approximately 20 ml during the
procedure and counting of only 5 ml of this solution in the
well counter.
Rosenspire et al. (1990) also proposed a simplified
solid phase extraction procedure, using separation into
only two fractions,
13N-ammonia and
13N-metabolites.
However, in our hands this procedure overestimated the
13N-ammonia fraction because of insufficient removal of
especially
13N-urea.
Radio-HPLC
Radio-HPLC was used for validation of the solid phase
extraction procedure. The radio-HPLC analysis of
13N-
ammonia and
13N-metabolites was adopted from Nieves et
al. (1986), using a cation exchange HPLC column with two
Fig. 1 Diagram of sequential solid phase fraction extraction proce-
dure for determination of
13N-metabolites
Table 1 Reproducibility of the modified sequential solid phase
extraction procedure for measurement of 1
3N-labelled metabolites in
blood
13N-glutamate
13N-ammonia
13N-glutamine
13N-urea
Coefficient
of variation
(%)
1.5
(0.1–7)
7.7
(0–28.9)
11.2
(0.1–42.5)
17.9
(0–57.3)
Data are shown as mean and range of coefficients of variation between
two measurements of
13N-fractions in blood samples taken 1–30 min
after intravenous administration of 500 MBq
13N-ammonia to 5
cirrhotic patients without HE (Fig. 2). For each metabolite the lowest
value is from the 1-min time point and the highest value from the 30-
min time point
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one blood sample was 25–30 min. Because of this and the
physical half-life of
13N of 10 min, we restricted the use of
the radio-HPLC analysis to blood samples taken 5 and
15 min after tracer injection (from Keiding et al. 2006).
When compared to the radio-HPLC results, the solid
phase extraction procedure yielded valid estimates of the
individual
13N-metabolite fractions.
Results and discussion
Reproducibility
The reproducibility study showed no significant difference
between the two time courses of the
13N-ammonia fractions
for any of the 5 subjects (Fig. 2) or any of the other
13N-
fractions. Coefficients of variation for each of the four
fractions indicate good reproducibility being best in the first
minutes after the
13N-ammonia tracer injection due to better
counting statistics (Table 1). Overall, measurement accuracy
was fine for the present purpose.
Time course of
13N-metabolite fractions
The time courses of the
13N-ammonia fractions after tracer
injection in the three groups of human subjects in Keiding
et al. (2006) are shown in Fig. 3 and typical examples of the
time course of the
13N-metabolite fractions in a cirrhotic
patient with HE and a healthy subject are shown in Fig. 4
(from Keiding et al. 2006).
13N-urea and
13N-glutamine
appeared at a slower rate in the cirrhotic patients than in the
healthy subjects, as illustrated in Fig. 4. Both the
13N-
ammonia fractions and the
13N-metabolite fractions had an
initial time delay of a little less than 1 min. This can be
ascribed to combined effects of blood circulation time and
time delay for formation of
13N-metabolites. The 30-min
time courses of the
13N-ammonia fractions were described
adequately by double exponential curves with an initial
time delay (Fig. 3 and Table 2). The decreasing
13N-
ammonia fraction was divided into of an initial fast
component (A and α) and a final slow component
0
Fig. 2 Reproducibility study. Time courses of the
13N-ammonia
fractions in arterial blood in 5 cirrhotic patients without HE, each
studied by two successive
13N-ammonia injections with a 60-min
interval. Data points from the two injections in a patient are shown by
similar symbols, being open and closed, respectively, and points from
each injection are connected by lines with the same type of line
Fig. 3 Time course of fractions of
13N-ammonia in arterial blood in
three groups of subjects as indicated (from Keiding et al. 2006).
Curves are double exponential fits (see Table 2)
52 Metab Brain Dis (2010) 25:49–56((100%–A) and β) (Table 2). We ascribe the fast compo-
nent as the result of metabolic conversion of the injected
13N-ammonia into
13N-metabolites, see also Fig. 4.
The metabolic conversion of
13N-ammonia comprised a
larger part in the group of healthy subjects (A=90%) than
in the two groups of patients with cirrhosis (77% and 78%,
respectively) and it was slower in the group of cirrhotic
patients with HE (α, 0.22 min
-1) than in the two other
groups of subjects (α, 0.35 min
-1 in both groups) (Table 2).
Overall the data thus indicate that the metabolic conversion
of ammonia took place in the order: healthy subjects >
cirrhotic patients without HE > cirrhotic patients with HE.
It is noticeably that the subsequent slow component does
not approximate zero within the present 30-min study
period. It is influenced not only by continued metabolic
conversion of
13N-ammonia, but also by formation of
13N-
ammonia from breakdown of
13N-glutamine in muscle
tissue (Duda and Handler 1958; Mobley and Hausinger
1989; Cooper 2001; Nishiguchi et al. 2003; Sørensen and
Keiding 2006), breakdown of
13N-urea by ureases in the
intestines (Prior and Visek 1972; Hansen and Vilstrup
1985; Mobley and Hausinger 1989) and unequal volumes
of distribution of the formed metabolites (Berl et al. 1962).
In our brain PETstudy we found that separate accounting
for blood
13N metabolites improved the goodness of the
kinetic fitting as evaluated by residuals of the fits when
compared with a model ignoring the time courses of the
metabolites (Keiding et al. 2006).
Time courses of
13N-ammonia concentrations and body
clearance of
13N-ammonia
The time course of the
13N-ammonia concentration in blood
was calculated from the measured total
13N-concentration
(Fig. 5) and the
13N-ammonia fractions (Fig. 4 and Table 2)
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Fig. 4 Examplesof
13N-metabolite fractions in arterial blood in a cirrhotic
patient with HE (closed symbols) and a healthy subject (open symbols)
Table 2 Parameters from fitting double exponential equations to the
time courses of
13N-ammonia fractions in arterial blood (from Keiding
et al. 2006) following iv 500 MBq
13N-ammonia tracer injection:
13N-
ammonia fraction = Ae α t td ðÞ þ 100   A ðÞ e β t td ðÞ .T h e
13N-ammo-
nia fraction is 100% between t=0 and t=td
Parameter
a Healthy subjects Cirrhotic patients
without HE
Cirrhotic patients
with HE
td (min) 0.95 0.99 0.91
A (%) 90 77 78
α (min
-1) 0.35 0.35 0.22
β (min
-1) 0.4 10
-2 2.2 10
-2 0.4 10
-2
aDouble exponential equation:
13N-ammonia fraction (%); t is time
after tracer injection (min); td is time delay between tracer injection
and appearance of
13N-metabolites in blood (min); A and (100%–A)
are the coefficients (%); α and β are exponents of the fast and slow
components, respectively (min
-1)
Fig. 5 Time-courses of blood concentrations of total
13N-radioactivity
concentrations (black) and of
13N-ammonia (red) and
13N-metabolites
(blue and black) after intravenous injection of 500 MBq
13N-ammonia
tracer to a cirrhotic patient with HE (upper graph) and a healthy
subject (lower graph). The time-courses of
13N-urea and
13N-
glutamine are coincident in the healthy subject
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of
13N-ammonia depends on
13N-metabolite formation and
distribution of
13N-ammonia and
13N-metabolites. In
general, blood concentration of
13N-ammonia decreased
faster and to a lower level within the present experimental
period the healthy subjects than in the patients with
cirrhosis (Fig. 5 shows an example). We therefore tested
the hypothesis that whole-body clearance of ammonia was
decreased in the patients with cirrhosis (Sørensen and
Keiding 2006). All subjects received the same dose of
13N-
ammonia tracer, and we therefore used the areas-under-the-
curve of the
13N-ammonia concentrations as approximate
“inverse” estimates of whole-body clearance of ammonia
(Fig. 6). It is seen that AUC was approximately the same in
cirrhotic patients without HE and healthy subjects and that
it was significantly higher in cirrhotic patients with HE than
in the two other groups of subjects, meaning that the
patients with HE had a lower body clearance than the two
other groups of subjects. Taken together with the above
analysis of the time course of the
13N-ammonia fractions,
the data strongly indicate that metabolic conversion of
ammonia is reduced in patients with de-compensated
cirrhosis (here HE).
Thefindingofalowerbodyclearanceofammoniacirrhotic
patients with HE than cirrhotic patients without HE again
underline the connection between blood ammonia and HE
(Keiding et al. 2006; Iversen et al. 2009), especially because
the uptake of ammonia into the brain is linearly correlated to
the blood concentration of ammonia (Lockwood et al. 1979;
Keiding et al. 2006).
Cerebral
13N-ammonia kinetics and blood-brain-barrier
for ammonia
It has been argued that the initial brain ammonia PET
kinetics can be analyzed adequately using total blood
13N-
concentrations without correction for
13N-metabolites (Ahl
et al. 2004). We tested this assumption by comparing the
initial unidirectional clearance (K1) using
13N-ammonia
concentration and total
13N-concentration as input function,
respectively, in a kinetic analysis according to the diagram
of the metabolic processes shown in Fig. 7 (Sørensen and
Keiding 2006). As illustrated in Fig. 8, there was a slight
tendency for higher K1 estimates using whole-blood
13N-
concentration than
13N-ammonia concentrations at low K1
values, whereas the opposite was the case for high values of
Fig. 6 Area under the curves (AUC) of blood concentrations of
13N-
ammonia in the groups of patients indicated (adapted from Sørensen
and Keiding 2006). Since the same dose of
13N-ammonia tracer was
given to all subjects (500 MBq), the AUCs reflect “inverse” whole-
body ammonia clearance estimates. Data are given as mean ± standard
error of the mean
Fig. 7 Simplified diagram of ammonia metabolism in brain: K1 is the
unidirectional clearance of
13N-ammonia from blood into cells (ml
blood/min/ml tissue), Kmet is the net metabolic clearance of
13N-
ammonia from blood into intracellular of
13N-metabolites (ml blood/
min/ml tissue), k2 the rate constant for back-flux from cell to blood of
un-metabolized
13N-ammonia (min
-1), and k3 the rate constant for
conversion of
13N-ammonia to
13N-metabolites (min
-1)
Fig. 8 Plot of the unidirectional clearance K1 calculated from the
model shown in Fig. 7, using either whole-blood
13N-concentration
(Y-axis)o r
13N-ammonia concentration (X-axis) as input function
using the individual PET-data from the groups of patients indicated
(adapted from Sørensen and Keiding 2006)
54 Metab Brain Dis (2010) 25:49–56K1. However, the difference from unity was not significant,
and similarly there were no significant differences between
healthy subjects and the two groups of patients with
cirrhosis. Hence it is acceptable to use whole-blood
13N-
concentrations as input function for assessment of initial
brain ammonia kinetics, including estimates of the blood-
brain-barrier permeability for ammonia. In this connection
it must be emphasized however, that the use of total
13N-
concentration as input function for calculation of parame-
ters for metabolic processes during quasi steady-state such
as for example the net metabolic clearance (Kmet, Fig. 7)
inevitably will yield incorrect results (Sørensen and Keiding
2006; Bass et al. 2009). The finding of a significant back-
flux of
13N-ammonia from brain to blood (Fig. 7)a s
quantified by Kmet <K 1 in each of the subjects from
Keiding et al. (2006) (Sørensen et al. 2009) would not have
been possible without using
13N-ammonia concentrations
as input functions in the kinetic analyses.
Conclusion
Our fractionation of
13N-content in blood is based on
modification and duplication of the original sequential solid
phase extraction procedure proposed by Rosenspire et al.
(1990). Recent PET-studies of brain ammonia kinetics,
using this procedure (Keiding et al. 2006) underline the
importance of using
13N-metabolite-corrected blood input
curves for assessment of organ ammonia metabolism. The
modified procedure thus enables analysis of enough blood
samples to perform detailed kinetic analysis of dynamic
13N-ammonia PET studies including steady-state ammonia
metabolism in brain and liver.
The present analysis of the time courses of the
13N-
ammonia and
13N-metabolite curves furthermore indicate
that the metabolic conversion of ammonia took place in the
order: healthy subjects > cirrhotic patients without HE >
cirrhotic patients with HE.
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